Company Description
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.
The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ICLUSIG (ponatinib), a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma; and NIKTIMVO (axatilimab-csfr) for treating chronic graft-versus-host disease, as well as OPZELURA (ruxolitinib) cream for treating atopic dermatitis.
Its clinical stage products include INCB123667 (CDK2) for ovarian cancer; INCB161734 (KRASG12D) for cancers; INCA33890 (TGFβR2xPD-1) for solid tumors; Ruxolitinib cream for mild to moderate hidradenitis suppurativa (HS); Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma and chronic spontaneous urticaria; INCB000262 (MRGPRX2) and INCB000547 (MRGPRX4) for systemic immune and neuro-immune disorders; INCA034460 (anti-CD122) for vitiligo; and Zilurgisertib (ALK2) for fibrodysplasia ossificans progressive.
It has collaboration with Genesis Therapeutics, Inc. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and specialty distributors and wholesalers.
The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003.
Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
| Country | United States |
| Founded | 1991 |
| IPO Date | Nov 4, 1993 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2,617 |
| CEO | Herve Hoppenot |
Contact Details
Address: 1801 Augustine Cut-Off Wilmington, Delaware 19803 United States | |
| Phone | 302 498 6700 |
| Website | incyte.com |
Stock Details
| Ticker Symbol | INCY |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000879169 |
| CUSIP Number | 45337C102 |
| ISIN Number | US45337C1027 |
| Employer ID | 94-3136539 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Herve Hoppenot | Chairman, President and Chief Executive Officer |
| Dr. Pablo J. Cagnoni M.D., Ph.D. | President and Head of Research and Development |
| Christiana Stamoulis M.B.A. | Executive Vice President and Chief Financial Officer |
| Dr. Steven H. Stein M.D. | Executive Vice President and Chief Medical Officer |
| Thomas Tray | Vice President of Finance, Chief Accounting Officer and Controller |
| Michael James Morrissey | Executive Vice President and Head of Global Technical Operations |
| Ben Strain | Head of Investor Relations |
| Sheila A. Denton J.D. | Executive Vice President, General Counsel and Corporate Secretary |
| Pamela M. Murphy | Vice President of Investor Relations and Corporate Communications |
| Paula J. Swain | Executive Vice President of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 14, 2025 | 144 | Filing |
| Mar 4, 2025 | 144 | Filing |
| Feb 26, 2025 | 144 | Filing |
| Feb 10, 2025 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Feb 10, 2025 | 10-K | Annual Report |
| Feb 10, 2025 | 8-K | Current Report |
| Jan 21, 2025 | 144 | Filing |
| Jan 10, 2025 | 8-K | Current Report |
| Dec 16, 2024 | 144 | Filing |
| Nov 29, 2024 | 144 | Filing |